BioWin

If you're at BIO-Europe in Stockholm, don’t miss our COO, David Honba, speaking on the panel “Blooming: Europe’s ATMPs - Leading the Way in Advanced Therapy,” starting shortly! David and other leading experts will share insights on Advanced Therapy Medicinal Products (ATMPs) across Europe, discussing collaboration, funding, and solutions to key challenges in clinical development, finance, and workforce training. Moderator: Anna Papageorgiou Panelists: Marzena Flasza-Baron, David Honba, Kristina Levan Wallonia Export & Investment Agency, BioWin

✨The HST Group - Health, Science and Technology Group has been integral to the organisation of Science for health 2024! Made up of biopharma heavyweights Pfizer, UCB, Johnson & Johnson and GSK, the HST Group aims to accelerate innovation, develop talents, attract investments and direct sustainable access to better health. We had the pleasure of sitting down with HST President Emmanuel Amory last week to pick his brain on the use of AI and data in #healthcare and the #pharmaceutical industry. Emmanuel talked about how data could be used to speed up health innovation, how AI can speed up drug discovery and support clinical trials, what should be considered in the development and regulation of AI, and what Belgium needs to maintain its standing as a leader in health- and biotech. 👉 Read the interview here: https://lnkd.in/e8JtnBxp -------- It’s nearly time for the big event ! Join us in Brussels for the eye-opening talks, the networking opportunities, and the sizzling debates! 🔥🔥 📆12 November 2024 📍SQUARE, Brussels ✍️Info and registration here: https://lnkd.in/gQpHPQ9

Interested in learning how a €380 million initiative aims to improve the lives of 30 million rare disease patients in Europe? Join us at an online session on October 28, 2024, for the official presentation of the European Partnership on Rare Diseases (ERDERA), where over 170+ organisations will collaborate to drive cutting-edge research. Hear from prominent speakers, including representatives from the European Commission , EURORDIS-Rare Diseases Europe , and INSERM Institut national de la santé et de la recherche médicale , and join us in making Europe a leader in rare disease research. We look forward to your participation! 👉 https://loom.ly/roZC5QM Service public de Wallonie

Advanced Therapies form a rapidly growing and evolving area of therapeutic drug development, expected to reach a global value of 80 billion euro in 2032. To stay competitive, organisations must position themselves amongst the 1500 companies heavily investing in ATMPs – not an easy feat when there are so many moving parts in the value chain. While it can be tempting to try to go it alone, the fastest and most intelligent way to advance is by #advancingtogether. The event, Advanced Therapies in Belgium, provided such an opportunity, offering a space for innovative ideas and featuring speakers from the forefront of Belgian and international ATMP innovation.

We are happy to welcome, not two, but three new BioWin team members – Camille Blondiau, Florence De Jaegere and David Honba. Camille Blondiau, our new Event Manager, brings a fresh perspective to BioWin’s events, with over 10 years of experience in the non-profit sector, maximizing networking and collaboration opportunities for our members. With more than 20 years of experiences in the life sciences industry, Florence De Jaegere will guide high-potential, early-stage advanced therapies research projects, working closely with companies, universities and hospitals. As Senior Project Manager, she will manage project calls, coordinate expert evaluations, and provide strategic support to drive impactful innovation, while maintaining strong ties with BioWin's member organisations. David Honba, our new Chief Operating Officer, brings more than a decade of experience from several life science companies. He will support the execution of BioWin's strategy while overseeing day-to-day operations to enhance the region's competitiveness and develop new initiatives that should support the future growth of our ecosystem. Welcome to the team!

What is the Belgian recipe for an innovative ecosystem in advanced therapies? Read this interesting Paper from Deloitte, developed with input from BioWin and MEDVIA. It addresses the challenges in commercialising advanced therapies and highlights Belgium’s potential to become a biomanufacturing hub in Europe, thanks to its strong logistics, academic expertise, and infrastructure. 👉 Download the full report: https://lnkd.in/eKrAT5UP

Wonder who’s pitching at HealthTech Investor Summit this December? Or which European investors will be listening in? On the dedicated HTIS website, you’ll find both, plus the speakers and program. 👉 https://lnkd.in/egvP87GQ

Member news! NOVADIP Biosciences S.A. reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field. At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached or are steadily progressing towards complete bone healing. “We need more options to improve outcomes in bone healing, particularly for patients with co-morbidities like advanced age, diabetes and smoking,” said Philipp Leucht, MD, PhD, Vice Chair of Research, Department of Orthopedic Surgery at NYU Grossman School of Medicine. “These interim results suggest that NVDX3 may have the potential to address this unmet need.” 👉 Read the full release: https://lnkd.in/eHaizEfA

When innovators get together, good things happen. That was the case last Tuesday at our Advanced Therapies in Belgium event. We were inspired by the incredible industry leaders looking to advance the development and accessibility of next-generation therapies for patients. Collaboration between academia, industry, government, and patient associations is crucial to bringing these advanced therapies to market. Belgium has all the ingredients to become a global leader in this field, but we must work together! Key event highlights: 250+ ATMP experts from Belgium and key international stakeholders  175+ organisations, including startups, hospitals, universities & companies.  420+ partnering requests, highlighting interest in collaborative innovation. 280+ scheduled meetings, with plenty of potential partnerships ahead. Thank you to our sponsors, exhibitors, speakers, pitchers, supporters and participants! And a huge thank you to all of the strategic sponsors who made the event possible, including: UCB, Thermo Fisher Scientific, Aseptic Technologies, Johnson & Johnson, Deloitte, Wallonia Export & Investment Agency

💥They will be pitching at Advanced Therapies in Belgium tomorrow, 15 October, in Namur. Come and listen to them!